SynthesisAnnals of oncology : official journal of the European Society for Medical Oncology2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
Synthesis in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 107 citations in OpenAlex.
- Trial
- In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.Annals of hematology · 2020Trial
- Clinical Characteristics and Prognostic Analysis of EBV-Positive HIV-Associated Diffuse Large B-Cell Lymphoma in China: A Retrospective Single-Center Study.Current oncology (Toronto, Ont.) · 2026Article
- The Characteristics of Peripheral Blood Lymphocyte Subsets in HIV-related Diffuse Large B-cell Lymphoma Patients and Their Impact on Treatment Efficacy.Current HIV research · 2026Article
- Immunosenescence phenotypes and prognostic significance of CD8 + CD28- T cells in AIDS-related non-Hodgkin lymphoma.Annals of medicine · 2025Article
- A Single Centre Retrospective Cohort Analysis of HIV Associated Lymphoma from Northern India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- A promising prognostic model for patients with AIDS-related lymphoma in the combination antiretroviral therapy era.AIDS (London, England) · 2025Article
- Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.Biomolecules · 2025Review
- Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China.Annals of hematology · 2025Article
- Trends and projections of Non-Hodgkin lymphoma burden (1990-2040): a global burden of disease 2021 analysis.BMC public health · 2025Article
- Development of a novel prognostic nomogram for AIDS-associated diffuse large B-cell lymphoma: a retrospective study from northern China.Clinical and experimental medicine · 2025Article
- The role of autologous bone marrow transplantation in primary effusion lymphoma: a case report and literature review.Hematology, transfusion and cell therapy · 2024Review
- HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus.Clinical microbiology reviews · 2024Review
- Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.HemaSphere · 2024Article
- The AIDS and Cancer Specimen Resource (ACSR): HIV malignancy specimens and data available at no cost.AIDS research and therapy · 2023Review
- Diffuse Large B-Cell Lymphoma in the HIV Setting.Cancers · 2023Review
- A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.Cancer medicine · 2023Observational
- Primary central nervous system lymphoma: treatment access and outcomes in HIV positive patients in a minority rich cohort.Stem cell investigation · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 15 institutions in 5 countries.
Funding
Abstract
backgroundWe undertook the present analysis to examine the shifting influence of prognostic factors in HIV-positive patients diagnosed with aggressive non-Hodgkin lymphoma (NHL) over the last two decades. PATIENTS AND
methodsWe carried out a pooled analysis from an existing database of patients with AIDS-related lymphoma. Individual patient data had been obtained prior from prospective phase II or III clinical trials carried out between 1990 until 2010 in North America and Europe that studied chemo(immuno)therapy in HIV-positive patients diagnosed with AIDS-related lymphomas. Studies had been identified by a systematic review. We analyzed patient-level data for 1546 patients with AIDS-related lymphomas using logistic regression and Cox proportional hazard models to identify the association of patient-, lymphoma-, and HIV-specific variables with the outcomes complete response (CR), progression-free survival, and overall survival (OS) in different eras: pre-cART (1989-1995), early cART (1996-2000), recent cART (2001-2004), and contemporary cART era (2005-2010).
resultsOutcomes for patients with AIDS-related diffuse large B-cell lymphoma and Burkitt lymphoma improved significantly over time, irrespective of baseline CD4 count or age-adjusted International Prognostic Index (IPI) risk category. Two-year OS was best in the contemporary era: 67% and 75% compared with 24% and 37% in the pre-cART era (P < 0.001). While the age-adjusted IPI was a significant predictor of outcome in all time periods, the influence of other factors waxed and waned. Individual HIV-related factors such as low CD4 counts (<50/mm(3)) and prior history of AIDS were no longer associated with poor outcomes in the contemporary era.
conclusionsOur results demonstrate a significant improvement of CR rate and survival for all patients with AIDS-related lymphomas. Effective HIV-directed therapies reduce the impact of HIV-related prognostic factors on outcomes and allow curative antilymphoma therapy for the majority of patients with aggressive NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.